ArticleNature communications2021
A human monoclonal antibody blocks malaria transmission and defines a highly conserved neutralizing epitope on gametes.
Erratum issued Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05135273 (Phase 1, Dose-Escalating, Double-Blind, Randomized, Comparator-Controlled Trial of the Safety, Tolerability, and Immunogenicity of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M™ Against Plasmodium Falciparum in Adults in Mali), which is not on this map. Cited by 50 papers.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 1, Dose-Escalating, Double-Blind, Randomized, Comparator-Controlled Trial of the Safety, Tolerability, and Immunogenicity of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M™ Against Plasmodium Falciparum in Adults in Mali
Who cites it
50 citing papers in PubMed, 67 citations in OpenAlex.
- The transmission-blocking dynamics of Plasmodium falciparum sexual-stage antibody responses in a six-year cohort of Ugandan children and adults.Nature communications · 2026Article
- Genetic diversity of the Plasmodium falciparum Pfs230 gene in four East African countries supports its potential as a malaria transmission‑blocking vaccine candidate.Malaria journal · 2026Article
- The kinetics and transmission-blocking dynamics ofResearch square · 2026Article
- Epitope-specific competitive ELISA predicts malaria transmission-blocking vaccine Pfs230D1 activity measured in standard membrane feeding assay.JCI insight · 2026Article
- A stabilized tandem antigen chimera that elicits potent malaria transmission-reducing activity.Nature communications · 2026Article
- Pfs230 domain 12 is a potent malaria transmission-blocking vaccine candidate.Science advances · 2025Article
- Article
- Structure of endogenous Pfs230:Pfs48/45 in complex with potent malaria transmission-blocking antibodies.bioRxiv : the preprint server for biology · 2025Article
- Review
- Targeting Bottlenecks in Malaria Transmission: Antibody-Epitope Descriptions Guide the Design of Next-Generation Biomedical Interventions.Immunological reviews · 2025Review
- Article
- Malaria vaccines: a new era of prevention and control.Nature reviews. Microbiology · 2024Review
- Multistage protective anti-CelTOS monoclonal antibodies with cross-species sterile protection against malaria.Nature communications · 2024Article
- Antibody gene features associated with binding and functional activity in malaria vaccine-derived human mAbs.NPJ vaccines · 2024Article
- Diversity and selection analyses identify transmission-blocking antigens as the optimal vaccine candidates in Plasmodium falciparum.EBioMedicine · 2024Article
- Vaccines and monoclonal antibodies: new tools for malaria control.Clinical microbiology reviews · 2024Review
- Diversity and selection analyses identify transmission-blocking antigens as the optimal vaccine candidates inmedRxiv : the preprint server for health sciences · 2024Article
- Production and use of antigen tetramers to study antigen-specific B cells.Nature protocols · 2024Review
- mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response.NPJ vaccines · 2024Article
- Development of an anti-Pfs230 monoclonal antibody as a Plasmodium falciparum gametocyte blocker.Research square · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
30 authors at 5 institutions in 4 countries.
Camila H Coelho *Pathogenesis and Immunity Section, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Wai Kwan Tang *Host-Pathogen Interactions and Structural Vaccinology Section, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Martin BurkhardtVaccine Development Unit, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Jacob D GalsonDivision of Immunology and Children's Research Center, University Children's Hospital Zurich, University of Zurich (UZH), Zurich, Switzerland.ORCID http://orcid.org/0000-0003-4916-800X
Olga MuratovaVaccine Development Unit, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Nichole D SalinasHost-Pathogen Interactions and Structural Vaccinology Section, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Thiago Luiz Alves E SilvaLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
Karine ReiterVaccine Development Unit, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Nicholas J MacDonaldVaccine Development Unit, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-8162-4514
Vu NguyenVaccine Development Unit, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Raul HerreraVaccine Development Unit, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Richard ShimpVaccine Development Unit, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
David L NarumVaccine Development Unit, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-3041-5402
Miranda Byrne-SteeleiRepertoire Inc., Huntsville, AL, USA.
Wenjing PaniRepertoire Inc., Huntsville, AL, USA.
Xiaohong HouiRepertoire Inc., Huntsville, AL, USA.
Brittany BrowniRepertoire Inc., Huntsville, AL, USA.
Mary EisenhoweriRepertoire Inc., Huntsville, AL, USA.
Jian HaniRepertoire Inc., Huntsville, AL, USA.
Bethany J JenkinsPathogenesis and Immunity Section, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Justin Y A DoritchamouPathogenesis and Immunity Section, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-4589-7216
Margery G SmelkinsonBiological Imaging Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-7777-5574
Joel Vega-RodríguezLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
Johannes TrückDivision of Immunology and Children's Research Center, University Children's Hospital Zurich, University of Zurich (UZH), Zurich, Switzerland.ORCID http://orcid.org/0000-0002-0418-7381
Justin J TaylorFred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-9718-2901
Issaka SagaraMalaria Research and Training Center, University of Sciences, Techniques, and Technology, Bamako, Mali.
Sara A HealyVaccine Development Unit, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Jonathan P RennVaccine Development Unit, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Niraj H ToliaHost-Pathogen Interactions and Structural Vaccinology Section, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. niraj.tolia@nih.gov.ORCID http://orcid.org/0000-0002-2689-1337
Patrick E DuffyPathogenesis and Immunity Section, Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. patrick.duffy@nih.gov.ORCID http://orcid.org/0000-0002-4483-5005
National Institutes of Health · USiRepertoire (United States) · USUniversity of Zurich · CHFred Hutch Cancer Center · USUniversity of Bamako · ML
Funding
Infectious Diseases Research Technologies Core - BethesdaZICAI001051 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHERRY, JAMES · 2009 to 2025
$226.1MVaccines to Interrupt Malaria Transmission: Clinical DevelopmentZIAAI001009 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DUFFY, PATRICK · 2009 to 2025
$84.8MMali International Center for Excellence in Research: Malaria Clinical ResearchZIAAI001056 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DUFFY, PATRICK · 2009 to 2024
$43.1MVaccines to Interrupt Malaria Transmission: Discovery and AssaysZIAAI001007 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DUFFY, PATRICK · 2009 to 2025
$28.9MHost-parasite-vector interactions during malaria transmissionZIAAI001250 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI VEGA-RODRIGUEZ, JOEL · 2019 to 2025
$9.9MMechanisms of effective antibody neutralization of malaria parasitesZIAAI001236 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI TOLIA, NIRAJ · 2018 to 2025
$6.6MAbstract
Malaria elimination requires tools that interrupt parasite transmission. Here, we characterize B cell receptor responses among Malian adults vaccinated against the first domain of the cysteine-rich 230 kDa gamete surface protein Pfs230, a key protein in sexual stage development of P. falciparum parasites. Among nine Pfs230 human monoclonal antibodies (mAbs) that we generated, one potently blocks transmission to mosquitoes in a complement-dependent manner and reacts to the gamete surface; the other eight show only low or no blocking activity. The structure of the transmission-blocking mAb in complex with vaccine antigen reveals a large discontinuous conformational epitope, specific to domain 1 of Pfs230 and comprising six structural elements in the protein. The epitope is conserved, suggesting the transmission-blocking mAb is broadly functional. This study provides a rational basis to improve malaria vaccines and develop therapeutic antibodies for malaria elimination.
Indexed as
AdultAnimalsAntibodies, MonoclonalAntibodies, ProtozoanAntigens, ProtozoanBinding SitesCells, CulturedEpitopesGerm CellsHost-Parasite InteractionsHumansMalaria, FalciparumMalaria VaccinesMosquito VectorsPlasmodium falciparumProtein ConformationAntibodies, MonoclonalAntibodies, ProtozoanAntigens, ProtozoanEpitopesMalaria VaccinesPfs230 antigen, Plasmodium falciparumProtozoan Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT05135273ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.